

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Vinda International Holdings Limited**  
**維達國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 3331)**

**INSIDE INFORMATION**

**UNAUDITED FINANCIAL INFORMATION  
FOR THE THREE MONTHS ENDED 30 SEPTEMBER 2022  
AND NINE MONTHS ENDED 30 SEPTEMBER 2022 OF  
VINDA INTERNATIONAL HOLDINGS LIMITED  
AND  
UNAUDITED FINANCIAL INFORMATION  
FOR THE THREE MONTHS ENDED 30 SEPTEMBER 2022  
AND NINE MONTHS ENDED 30 SEPTEMBER 2022 OF  
THE CONTROLLING SHAREHOLDER**

The board of directors (the “**Board**”) of Vinda International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce the unaudited financial information of the Group’s business for the three months ended 30 September 2022 (“**Q3 2022**”) and nine months ended 30 September 2022 (“**M9 2022**”).

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

## **UNAUDITED FINANCIAL INFORMATION FOR Q3 2022 AND M9 2022 OF THE GROUP**

The Group's third quarter results reflect a challenging and volatile operating environment, as we face pressure from unprecedented input cost inflation, operational disruptions from COVID related measures and currency swings. Organic sales were strong with increase in both volume and selling prices. During the period, earnings were negatively impacted by significant increases in input costs, which were partially offset by multiple pricing initiatives, continuous improvement in efficiency and mix improvement. Looking ahead, the Group will continue to focus in strengthening our long-term competitiveness with committed investment in brand building and innovation, while leveraging pricing, premiumization and cost discipline to mitigate cost headwinds to improve margin over time.

### **Compared to the three months ended 30 September 2021 ("Q3 2021"), the unaudited financial information of the Group for Q3 2022:**

- Total revenue increased by 6.5% (12.9% at constant exchange rates) to HK\$4,374 million, of which HK\$3,599 million was from the tissue segment and HK\$775 million was from the personal care segment.
- Gross profit dropped by 17.1% to HK\$1,191 million. Gross margin narrowed by 7.8 percentage points ("**ppts**") to 27.2%.
- Total foreign exchange loss was HK\$54.1 million (Q3 2021: HK\$7.5 million loss), of which HK\$51.1 million loss was from operating activities (Q3 2021: HK\$6.7 million loss), and HK\$3.0 million loss was from financing activities (Q3 2021: HK\$0.9 million loss).
- Operating profit dropped by 78.2% to HK\$77 million. Operating margin narrowed by 6.8 ppts to 1.8%. If excluding the foreign exchange loss from operating activities, operating margin would be 2.9%.
- EBITDA recorded a decrease of 40.1% to HK\$399 million with a corresponding EBITDA margin reduced by 7.1 ppts to 9.1%.

**Compared to the nine months ended 30 September 2021 (“M9 2021”), the unaudited financial information of the Group for M9 2022:**

- Total revenue increased by 6.6% (8.8% at constant exchange rates) to HK\$14,055 million, of which HK\$11,562 million was from the tissue segment and HK\$2,492 million was from the personal care segment.
- Gross profit decreased by 11.2% to HK\$4,291 million with a corresponding gross margin of 30.5%, decreased by 6.1 ppts.
- Total foreign exchange loss was HK\$76.5 million (M9 2021: HK\$0.9 million loss), of which HK\$77.3 million loss was from operating activities (M9 2021: HK\$1.0 million loss), and HK\$0.8 million gain was from financing activities (M9 2021: HK\$0.1 million gain).
- Operating profit dropped by 46.7% to HK\$834 million with a corresponding operating margin of 5.9%, narrowed by 6.0 ppts. If excluding the foreign exchange loss from operating activities, operating margin would be 6.5%.
- EBITDA decreased by 27.1% to HK\$1,817 million with a corresponding EBITDA margin declined by 6.0 ppts to 12.9%.

**UNAUDITED FINANCIAL INFORMATION FOR Q3 2022 AND M9 2022 OF ESSITY AKTIEBOLAG (PUBL)**

Essity Aktiebolag (publ) (“**Essity**”), the Company’s controlling shareholder, is a company listed on NASDAQ OMX Stockholm. As at the date of this announcement, Essity beneficially owns approximately 51.59% of the entire issued share capital of the Company.

Essity files financial reports which include quarterly financial information and certain operating statistics on a quarterly basis in accordance with the ongoing disclosure obligations applicable to a publicly traded listed company on NASDAQ OMX Stockholm. Such reports include segment financial information on the operations of the Company and are available in the public domain.

Essity will on or about 27 October 2022 release its unaudited financial results for the third quarter ended 30 September 2022. For details, please visit Essity’s website: [www.essity.com](http://www.essity.com).

Shareholders and potential investors of the Company are advised that there is no indication or assurance from the Company that the unaudited financial information of the Group for Q3 2022 and M9 2022 will be the same as that presented in Essity's report for the third quarter of 2022.

Potential investors and shareholders of the Company are reminded that the above financial information has not been reviewed or audited by the Company's independent auditors. Subject to review and audit adjustment, differences may arise between such financial information and the data disclosed in the audited report. Potential investors and shareholders of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board  
**Vinda International Holdings Limited**  
**LI Chao Wang**  
*Chairman*

Hong Kong, China, 17 October 2022

*As at the date of this announcement, the Board comprises:*

*Executive Directors:*

Mr. LI Chao Wang  
Ms. YU Yi Fang  
Ms. LI Jielin  
Mr. DONG Yi Ping

*Non-Executive Directors:*

Mr. Jan Christer JOHANSSON  
Mr. Carl Magnus GROTH  
Mr. Carl Fredrik Stenson RYSTEDT  
Mr. Johann Christoph MICHALSKI

*Independent Non-Executive Directors:*

Mr. TSUI King Fai  
Mr. WONG Kwai Huen, Albert  
Mr. LAW Hong Ping, Lawrence  
Dr. CAO Zhenlei

*Alternate Directors:*

Mr. Gert Mikael SCHMIDT (*alternate to Mr. JOHANSSON and Mr. GROTH*)  
Mr. Dominique Michel Jean DESCHAMPS (*alternate to Mr. RYSTEDT*)